ILLUMINATE: Efficacy and Safety of Durvalumab/ Tremelimumab and Chemotherapy in EGFR-Mutant NSCLC Following Progression on EGFR Inhibitors

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [21] Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
    Riess, J.
    Kelly, K.
    Schalper, K.
    Shimoda, M.
    Lim, S.
    Monjazeb, A.
    Danenberg, K.
    Moore, E.
    Beckett, L.
    Mack, P.
    Maverakis, E.
    Gandara, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S528 - S528
  • [22] Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations
    Li, Xuefei
    Cai, Weijing
    Yang, Guohua
    Su, Chunxia
    Ren, Shengxiang
    Zhao, Chao
    Hu, Rongjun
    Chen, Xiaoxia
    Gao, Guanghui
    Guo, Zhiwei
    Li, Wei
    Zhou, Caicun
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (09) : 1388 - 1397
  • [23] Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC
    Zhao, Binghao
    Yao, Longping
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05)
  • [24] Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC
    Wang, P.
    Li, Y.
    Lv, D.
    Ding, L.
    Hong, W.
    Han-Zhang, H.
    Lin, J.
    Zhou, J.
    Wang, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S598 - S599
  • [25] Cytoplasmic ERβ expression to predict efficacy and survival of EGFR-TKI in EGFR-mutant NSCLC
    Wang, Zhijie
    Wang, Jie
    Wang, Xiaodong
    Shen, Zhirong
    Ding, Xiaosheng
    Bai, Hua
    Duan, Jianchun
    An, Tongtong
    Wang, Yuyan
    Zhuo, Minglei
    Wang, Shuhang
    Wu, Meina
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)
    Nassar, Amin
    Adib, Elio
    Feng, Jamie
    Aredo, Jacqueline V.
    Parikh, Kaushal
    Harris, Jeremy Phillip
    Manana, Ana I. Velazquez
    Ragavan, Meera Vimala
    Lin, Jessica Jiyeong
    Piotrowska, Zofia
    Fitzgerald, Bailey Gleason
    Grohe, Christian
    Sankar, Kamya
    Neal, Joel W.
    Wakelee, Heather A.
    Shepherd, Frances A.
    Herbst, Roy S.
    Naqash, Abdul Rafeh
    Goldberg, Sarah B.
    Kim, So Yeon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Safety and Efficacy of Cranial Radiotherapy in Combination with Aumolertinibin EGFR-Mutant NSCLC Patients with Brain Metastases
    Han, S.
    Wang, W.
    Bi, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S590 - S590
  • [28] Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
    Jassem, Jacek
    LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 808 - 810
  • [29] EGFR-mutant NSCLC: emerging novel drugs
    Ye, Lingyun
    Chen, Xiaoxia
    Zhou, Fei
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (01) : 87 - 94
  • [30] Amivantamab OK'd for EGFR-Mutant NSCLC
    Dolgin, Elie
    CANCER DISCOVERY, 2021, 11 (07) : 1604 - 1604
12345